Intratumoral budding and automated CD8-positive T-cell density in pretreatment biopsies can predict response to neoadjuvant therapy in rectal adenocarcinoma.
Adenocarcinoma
/ immunology
Aged
Aged, 80 and over
Automation, Laboratory
Biopsy
CD8-Positive T-Lymphocytes
/ immunology
Cell Movement
Chemoradiotherapy, Adjuvant
Clinical Decision-Making
Databases, Factual
Disease Progression
Disease-Free Survival
Female
Humans
Lymphocyte Count
Lymphocytes, Tumor-Infiltrating
/ immunology
Male
Middle Aged
Neoadjuvant Therapy
Neoplasm Recurrence, Local
Predictive Value of Tests
Rectal Neoplasms
/ immunology
Retrospective Studies
Risk Assessment
Risk Factors
Time Factors
Tumor Microenvironment
/ immunology
Journal
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
30
03
2020
accepted:
29
06
2020
revised:
29
06
2020
pubmed:
15
7
2020
medline:
4
11
2021
entrez:
15
7
2020
Statut:
ppublish
Résumé
Tumor budding and CD8-positive (+) T-cells are recognized as prognostic factors in colorectal adenocarcinoma. We assessed CD8+ T-cell density and intratumoral budding in pretreatment rectal cancer biopsies to determine if they are predictive biomarkers for response to neoadjuvant therapy and survival. Pretreatment biopsies of locally advanced rectal adenocarcinoma from 117 patients were evaluated for CD8+ T-cell density using automated quantitative digital image analysis and for intratumoral budding and correlated with clinicopathological variables on postneoadjuvant surgical resection specimens, response to neoadjuvant therapy, and survival. Patients with high CD8+ T-cell density (≥157 per mm
Identifiants
pubmed: 32661298
doi: 10.1038/s41379-020-0619-8
pii: S0893-3952(22)00404-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
171-183Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
pubmed: 31912902
Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, et al. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16:874–901.
doi: 10.6004/jnccn.2018.0061
Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol. 2014;32:1554–62.
doi: 10.1200/JCO.2013.54.3769
Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012;99:918–28.
doi: 10.1002/bjs.8702
Trakarnsanga A, Gonen M, Shia J, Nash GM, Temple LK, Guillem JG, et al. Comparison of tumor regression grade systems for locally advanced rectal cancer after multimodality treatment. J Natl Cancer Inst. 2014;106.
Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017;30:1299–311.
doi: 10.1038/modpathol.2017.46
Pages F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391:2128–39.
doi: 10.1016/S0140-6736(18)30789-X
Anitei MG, Zeitoun G, Mlecnik B, Marliot F, Haicheur N, Todosi AM, et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res. 2014;20:1891–9.
doi: 10.1158/1078-0432.CCR-13-2830
Akiyoshi T, Tanaka N, Kiyotani K, Gotoh O, Yamamoto N, Oba K, et al. Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer. Br J Surg. 2019;106:1381–92.
doi: 10.1002/bjs.11179
McCoy MJ, Hemmings C, Anyaegbu CC, Austin SJ, Lee-Pullen TF, Miller TJ, et al. Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response. Oncotarget. 2017;8:19803–13.
doi: 10.18632/oncotarget.15048
Yasuda K, Nirei T, Sunami E, Nagawa H, Kitayama J. Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer. Radiat Oncol. 2011;6:49.
doi: 10.1186/1748-717X-6-49
Giger OT, Comtesse SC, Lugli A, Zlobec I, Kurrer MO. Intra-tumoral budding in preoperative biopsy specimens predicts lymph node and distant metastasis in patients with colorectal cancer. Mod Pathol. 2012;25:1048–53.
doi: 10.1038/modpathol.2012.56
Lugli A, Vlajnic T, Giger O, Karamitopoulou E, Patsouris ES, Peros G, et al. Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients. Hum Pathol. 2011;42:1833–40.
doi: 10.1016/j.humpath.2011.02.010
Rogers AC, Gibbons D, Hanly AM, Hyland JM, O’Connell PR, Winter DC, et al. Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy. Mod Pathol. 2014;27:156–62.
doi: 10.1038/modpathol.2013.124
Hartman DJ, Frank M, Seigh L, Choudry H, Pingpank J, Holtzman M, et al. Automated quantitation of CD8-positive T cells predicts prognosis in colonic adenocarcinoma with mucinous, signet ring cell, or medullary differentiation independent of mismatch repair protein status. Am J Surg Pathol. 2020;44:991–1001.
Hartman DJ, Ahmad F, Ferris RL, Rimm DL, Pantanowitz L. Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. Oral Oncol. 2018;86:278–87.
doi: 10.1016/j.oraloncology.2018.10.005
Ma C, Olevian D, Miller C, Herbst C, Jayachandran P, Kozak MM, et al. SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer. Mod Pathol. 2019;32:1217–31.
doi: 10.1038/s41379-019-0265-1
Nagtegaal ID, Arends MJ, Salto-Tellez M. Colorectal adenocarcinoma. In: Arends MJ, Fukayama M, Klimstra DS, Lam AKY, Nagtegaal ID, Odze RD, et al. editors. WHO classification of tumours: digestive system tumours. 5th ed. Lyon, France: IARC Press; 2019. p. 177–87.
Klintrup K, Makinen JM, Kauppila S, Vare PO, Melkko J, Tuominen H, et al. Inflammation and prognosis in colorectal cancer. Eur J Cancer. 2005;41:2645–54.
doi: 10.1016/j.ejca.2005.07.017
Williams DS, Mouradov D, Jorissen RN, Newman MR, Amini E, Nickless DK, et al. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes. Gut. 2019;68:465–74.
doi: 10.1136/gutjnl-2017-315664
Jessup J, Goldberg R, Asare E, Benson III A, Brierley J, Chang G. Colon and rectum. AJCC Cancer Staging Manual. 8 ed. Chicago: AJCC; 2017. p. 251–83.
Kakar S, Shi C, Berho M, Driman D, Fitzgibbons P, Frankel W, et al. College of American pathologists: protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum college of American pathologists. 2017. https://documents.cap.org/protocols/cp-gilower-colonrectum-17protocol-4010.pdf .
Gavioli M, Luppi G, Losi L, Bertolini F, Santantonio M, Falchi AM, et al. Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer. Dis Colon Rectum. 2005;48:1851–7.
doi: 10.1007/s10350-005-0133-6
Karagkounis G, Thai L, Mace AG, Wiland H, Pai RK, Steele SR, et al. Prognostic implications of pathological response to neoadjuvant chemoradiation in pathologic stage III rectal cancer. Ann Surg. 2019;269:1117–23.
doi: 10.1097/SLA.0000000000002719
Mace AG, Pai RK, Stocchi L, Kalady MF. American joint committee on cancer and college of American pathologists regression grade: a new prognostic factor in rectal cancer. Dis Colon Rectum. 2015;58:32–44.
doi: 10.1097/DCR.0000000000000266
Park IJ, You YN, Agarwal A, Skibber JM, Rodriguez-Bigas MA, Eng C, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012;30:1770–6.
doi: 10.1200/JCO.2011.39.7901
Yoon HH, Shi Q, Heying EN, Muranyi A, Bredno J, Ough F, et al. Intertumoral heterogeneity of CD3(+) and CD8(+) T-cell densities in the microenvironment of DNA mismatch-repair-deficient colon cancers: implications for prognosis. Clin Cancer Res. 2019;25:125–33.
doi: 10.1158/1078-0432.CCR-18-1984
Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity. 2016;44:698–711.
doi: 10.1016/j.immuni.2016.02.025
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–4.
doi: 10.1126/science.1129139
Emile JF, Julie C, Le Malicot K, Lepage C, Tabernero J, Mini E, et al. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. Eur J Cancer. 2017;82:16–24.
doi: 10.1016/j.ejca.2017.04.025
Kamran SC, Lennerz JK, Margolis CA, Liu D, Reardon B, Wankowicz SA, et al. Integrative molecular characterization of resistance to neoadjuvant chemoradiation in rectal cancer. Clin Cancer Res. 2019;25:5561–71.
doi: 10.1158/1078-0432.CCR-19-0908
Araki K, Ebata T, Guo AK, Tobiume K, Wolf SJ, Kawauchi K. p53 regulates cytoskeleton remodeling to suppress tumor progression. Cell Mol Life Sci. 2015;72:4077–94.
doi: 10.1007/s00018-015-1989-9
Puisieux A, Brabletz T, Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol. 2014;16:488–94.
doi: 10.1038/ncb2976
Chen TW, Huang KC, Chiang SF, Chen WT, Ke TW, Chao KSC. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy. J Cancer Res Clin Oncol. 2019;145:1043–53.
doi: 10.1007/s00432-019-02874-7